Skip to main content

GT Biopharma, Inc.

corporate_fare Company Profile

GT Biopharma, Inc.

GTBP·NASDAQ·Life Sciences·CIK 0000109657

We are a clinical stage biopharmaceutical company focused on developing and commercializing new immuno-oncology products. Our products are based on our proprietary Tri-specific Killer Engager ("TriKE®") and Tetra-specific Killer Engager ("Dual Targeting TriKE®") fusion protein immune cell engager technology platforms. These platforms create proprietary therapeutics designed to harness and enhance the cancer-killing abilities of a patient's own natural killer cells ("NK cells"). Once bound to an NK cell, our molecules are designed to activate the NK cell to direct it to one or more specific proteins found on a particular type of cancer cell or virus-infected cell, leading to the death of the targeted cell. TriKE®s can be designed to target various tumor antigens, including B7-H3, HER2, CD33, and PDL1, on blood cancers or solid tumors and do not require patient-specific customization. We intend to use our TriKE® platform to bring immuno-oncology products to market that can treat a range of blood cancers, solid tumors, and potentially autoimmune disorders. The platform is scalable, and we are implementing processes to produce investigational new drug ("IND") ready molecules promptly after a specific TriKE® conceptual design. Specific drug candidates can then be advanced into clinical trials independently or through potential collaborations with partnering companies. Our initial work was conducted in collaboration with the Masonic Cancer Center at the University of Minnesota under a program led by Dr. Jeffrey Miller, Professor of Medicine, and the Interim Director at the Masonic Cancer Center.

GT Biopharma, Inc. (NASDAQ:GTBP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for GTBP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for GTBP spans 8-K, DEF 14A, PRE 14A, 10-Q.

Recent high-impact activity:

  • GT Biopharma Holders Approve 10x Authorized Share Increase to 250 Million
  • GT Biopharma Seeks Approval for 10x Share Increase and 61% Potential Control Shift to Private Placement Investors
  • Shareholders to Vote on 10x Authorized Share Increase and Potential 61% Control Shift at GT Biopharma
  • GT Biopharma Regains Nasdaq Minimum Bid Price Compliance
  • GT Biopharma Upsizes Private Placement to $7.75M, Adds New Purchaser

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$28.35M
Diluted EPS
-$6.68
Op. Cash Flow
-$12.91M
Operating Income
-$12.42M
Cash & Equivalents
$6.81M
Debt / Equity
0.00×
Shares Outstanding
25.53M sh
Source: 10-K · filed 2026-03-02 · accession 0001493152-26-008443

Short Interest & Short Volume

3.21 days to cover

FINRA reported short interest of 246,479 shares in GTBP as of the October 30, 2026 settlement, a 11.6% decrease from the prior period — about 3.2 days to cover at its recent average daily volume. On November 20, 2026, 48.3% of GTBP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)246,479 shares as of October 30, 2026
Change vs prior period▼ 11.6%
Days to cover3.21 at avg daily volume of 76,840
Daily short volume (FINRA facilities)48.3% of 17,983 shares on November 20, 2026
5-day average short volume55.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for GTBP, detected from its recent SEC filings.

1 shelf registrationreverse split

13.5M Shares Registered for Resale · Substantial Overhang vs. Current Float

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with G →
$2.77 -6.42% today
52-week range · as of 2026-11-12 $2.77 – $28.75
Market cap
$6.33M
Volume
39.7K (0.6× avg)
3-mo avg 71.4K
Live data · 2026-11-22 08:01 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GTBP - Latest Insights

GTBP
Nov 12, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.00
Real-time Price: $2.77 info
Change: -$1.23 (-31%) info
Market Cap: $6.326M info
GTBP
Oct 13, 2026, 5:00 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $6.50
Real-time Price: $2.77 info
Change: -$3.73 (-57%) info
Market Cap: $6.326M info
GTBP
Oct 02, 2026, 5:26 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $6.10
Real-time Price: $2.77 info
Change: -$3.33 (-55%) info
Market Cap: $6.326M info
GTBP
Sep 25, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.89
Real-time Price: $2.77 info
Change: -$4.12 (-60%) info
Market Cap: $6.326M info
GTBP
Sep 21, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.18
Real-time Price: $2.77 info
Change: -$4.41 (-61%) info
Market Cap: $6.326M info
GTBP
Sep 15, 2026, 9:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.29
Real-time Price: $2.77 info
Change: -$8.52 (-75%) info
Market Cap: $6.326M info
GTBP
Sep 15, 2026, 8:57 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $12.73
Real-time Price: $2.77 info
Change: -$9.96 (-78%) info
Market Cap: $6.326M info
GTBP
Sep 03, 2026, 11:45 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.2816
Real-time Price: $2.77 info
Change: Reverse Stock Split info
Market Cap: $6.326M info
GTBP
Aug 14, 2026, 8:01 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.295
Real-time Price: $2.77 info
Change: Reverse Stock Split info
Market Cap: $6.326M info
GTBP
Aug 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.295
Real-time Price: $2.77 info
Change: Reverse Stock Split info
Market Cap: $6.326M info
GTBP
Jun 18, 2026, 4:45 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $0.4871
Real-time Price: $2.77 info
Change: Reverse Stock Split info
Market Cap: $6.326M info
GTBP
May 22, 2026, 8:03 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.4409
Real-time Price: $2.77 info
Change: Reverse Stock Split info
Market Cap: $6.326M info
GTBP
May 22, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.440
Real-time Price: $2.77 info
Change: Reverse Stock Split info
Market Cap: $6.326M info
GTBP
May 15, 2026, 8:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.4371
Real-time Price: $2.77 info
Change: Reverse Stock Split info
Market Cap: $6.326M info
GTBP
May 15, 2026, 8:00 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.4371
Real-time Price: $2.77 info
Change: Reverse Stock Split info
Market Cap: $6.326M info
GTBP
May 13, 2026, 5:18 PM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $0.312
Real-time Price: $2.77 info
Change: Reverse Stock Split info
Market Cap: $6.326M info
GTBP
Apr 30, 2026, 4:55 PM EDT
Filing Type: S-1
Importance Score:
9
Price at Filing: $0.3101
Real-time Price: $2.77 info
Change: Reverse Stock Split info
Market Cap: $6.326M info
GTBP
Apr 07, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.445
Real-time Price: $2.77 info
Change: Reverse Stock Split info
Market Cap: $6.326M info
GTBP
Mar 06, 2026, 4:01 PM EST
Filing Type: 10-Q/A
Importance Score:
9
Price at Filing: $0.4693
Real-time Price: $2.77 info
Change: Reverse Stock Split info
Market Cap: $6.326M info
GTBP
Mar 06, 2026, 4:01 PM EST
Filing Type: 10-Q/A
Importance Score:
9
Price at Filing: $0.4693
Real-time Price: $2.77 info
Change: Reverse Stock Split info
Market Cap: $6.326M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets